Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Tumor cell‐specific 2′‐fluoro rna aptamer conjugated with closo‐dodecaborate as a potential agent for boron neutron capture therapy. / Vorobyeva, Mariya A.; Dymova, Maya A.; Novopashina, Darya S. и др.
в: International Journal of Molecular Sciences, Том 22, № 14, 7326, 02.07.2021.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Tumor cell‐specific 2′‐fluoro rna aptamer conjugated with closo‐dodecaborate as a potential agent for boron neutron capture therapy
AU - Vorobyeva, Mariya A.
AU - Dymova, Maya A.
AU - Novopashina, Darya S.
AU - Kuligina, Elena V.
AU - Timoshenko, Valentina V.
AU - Kolesnikov, Iaroslav A.
AU - Taskaev, Sergey Yu
AU - Richter, Vladimir A.
AU - Venyaminova, Alya G.
N1 - Funding Information: Funding: This research was funded by the Russian Science Foundation, grant number 19‐74‐20127. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/7/2
Y1 - 2021/7/2
N2 - Boron neutron capture therapy (BNCT) is a binary radiotherapeutic approach to the treatment of malignant tumors, especially glioblastoma, the most frequent and incurable brain tumor. For successful BNCT, a boron‐containing therapeutic agent should provide selective and effective accumulation of10B isotope inside target cells, which are then destroyed after neutron irradiation. Nucleic acid aptamers look like very prospective candidates for carrying10B to the tumor cells. This study represents the first example of using 2′‐F‐RNA aptamer GL44 specific to the human glioblas-toma U‐87 MG cells as a boron delivery agent for BNCT. The closo‐dodecaborate residue was at-tached to the 5′‐end of the aptamer, which was also labeled by the fluorophore at the 3′‐end. The resulting bifunctional conjugate showed effective and specific internalization into U‐87 MG cells and low toxicity. After incubation with the conjugate, the cells were irradiated by epithermal neu-trons on the Budker Institute of Nuclear Physics neutron source. Evaluation of the cell proliferation by real‐time cell monitoring and the clonogenic test revealed that boron‐loaded aptamer decreased specifically the viability of U‐87 MG cells to the extent comparable to that of10B‐boronophenylala-nine taken as a control. Therefore, we have demonstrated a proof of principle of employing ap-tamers for targeted delivery of boron‐10 isotope in BNCT. Considering their specificity, ease of syn-thesis, and large toolkit of chemical approaches for high boron‐loading, aptamers provide a prom-ising basis for engineering novel BNCT agents.
AB - Boron neutron capture therapy (BNCT) is a binary radiotherapeutic approach to the treatment of malignant tumors, especially glioblastoma, the most frequent and incurable brain tumor. For successful BNCT, a boron‐containing therapeutic agent should provide selective and effective accumulation of10B isotope inside target cells, which are then destroyed after neutron irradiation. Nucleic acid aptamers look like very prospective candidates for carrying10B to the tumor cells. This study represents the first example of using 2′‐F‐RNA aptamer GL44 specific to the human glioblas-toma U‐87 MG cells as a boron delivery agent for BNCT. The closo‐dodecaborate residue was at-tached to the 5′‐end of the aptamer, which was also labeled by the fluorophore at the 3′‐end. The resulting bifunctional conjugate showed effective and specific internalization into U‐87 MG cells and low toxicity. After incubation with the conjugate, the cells were irradiated by epithermal neu-trons on the Budker Institute of Nuclear Physics neutron source. Evaluation of the cell proliferation by real‐time cell monitoring and the clonogenic test revealed that boron‐loaded aptamer decreased specifically the viability of U‐87 MG cells to the extent comparable to that of10B‐boronophenylala-nine taken as a control. Therefore, we have demonstrated a proof of principle of employing ap-tamers for targeted delivery of boron‐10 isotope in BNCT. Considering their specificity, ease of syn-thesis, and large toolkit of chemical approaches for high boron‐loading, aptamers provide a prom-ising basis for engineering novel BNCT agents.
KW - Boron clusters
KW - Boron neutron capture therapy
KW - Cancer treatment
KW - Cell‐specific aptamers
KW - Drug delivery
KW - Human glioblastoma cells
KW - Cell Line
KW - Isotopes/pharmacology
KW - Boron Neutron Capture Therapy/methods
KW - Humans
KW - Neutrons/therapeutic use
KW - Boron Compounds/pharmacology
KW - Glioblastoma/radiotherapy
KW - Aptamers, Nucleotide/pharmacology
KW - Brain Neoplasms/rehabilitation
KW - Boron/pharmacology
KW - Cell Line, Tumor
KW - Cell Proliferation/radiation effects
UR - http://www.scopus.com/inward/record.url?scp=85109073590&partnerID=8YFLogxK
U2 - 10.3390/ijms22147326
DO - 10.3390/ijms22147326
M3 - Article
C2 - 34298946
AN - SCOPUS:85109073590
VL - 22
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 14
M1 - 7326
ER -
ID: 29231532